Tourangeau Greg 4

What Happened

• Greg Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics (FULC), received an award of 57,000 derivative shares (reported as an option/award) on February 2, 2026. The transaction is reported at an acquisition price of $0.00 because it is an equity award (not an open-market purchase or sale).

Key Details

• Transaction date and type: 2026-02-02 — Award/Grant (code A) of 57,000 derivative shares, reported at $0.00.
• Vesting: The option was granted Feb 2, 2026 and vests in equal quarterly installments over four years, beginning Jan 1, 2026, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Filing timeliness: Form 4 filed 2026-02-04 for a 2026-02-02 transaction — appears to be timely (within the usual two-business-day window).
• No indication in the filing that shares were sold or exercised as part of this transaction.

Context

• This was a granted equity award (derivative/option), not an immediate purchase or sale. Such grants are typically part of compensation and vest over time; they do not by themselves signal an immediate change in market exposure because the shares are subject to vesting and continued service requirements.